SCHEMBL1007193

SCHEMBL1007193

Cc1cc2nc(S)[nH]c2cc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.59
ATM Q13315 3/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
KMT2A Q03164 2/20 0.58
PSMD14 O00487 1/20 0.58
MMP2 P08253 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 1/20 0.57
CACNA1B Q00975 1/20 0.57
APBA1 Q02410 1/20 0.57
MCL1 Q07820 1/20 0.57
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ERAP1 Q9NZ08 1/20 0.45
METAP1 P53582 2/20 0.45
METAP2 P50579 1/20 0.45
CBFB Q13951 1/20 0.45
AMY1A P0DUB6 5/20 0.44
HRH4 Q9H3N8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10844887 0.91 MAPT (0.50) FABP6ATMMEN1MAPTKMT2A
SCHEMBL23041368 0.84 ATM (0.43) FABP6ATMMEN1MAPTKMT2A
SCHEMBL14502996 0.84 MEN1 (0.43) FABP6ATMMEN1MAPTKMT2A
SCHEMBL2108252 0.84 GRIN2D (0.44) FABP6ATMMEN1MAPTKMT2A
SCHEMBL9455942 0.81 AMY1A (0.47) FABP6ATMMEN1MAPTKMT2A
SCHEMBL16134553 0.81 MAPT (0.49) FABP6ATMMEN1MAPTKMT2A
SCHEMBL8314626 0.79 TUBB4A (0.40) FABP6ATMMEN1MAPTKMT2A
SCHEMBL9261531 0.79 TUBB4A (0.40) FABP6ATMMEN1MAPTKMT2A
SCHEMBL10846976 0.79 MAPT (0.39) FABP6ATMMEN1MAPTKMT2A
SCHEMBL10606917 0.77 HSD17B10 (0.41) FABP6ATMMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122051380-A Application of additive in lithium battery electrolyte, electrolyte and lithium battery 中国科学院大连化学物理研究所 2026-05-15 CN claimed
WO-2025071094-A1 USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY 부산대학교 산학협력단 2025-04-03 WO claimed
CN-122051380-A Application of additive in lithium battery electrolyte, electrolyte and lithium battery 中国科学院大连化学物理研究所 2026-05-15 CN disclosed
CN-120136899-A Azo/deuterated imidazothiazinone compound, synthetic method and application 新疆大学 2025-06-13 CN disclosed
WO-2025071094-A1 USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY 부산대학교 산학협력단 2025-04-03 WO disclosed
US-20240132479-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2024-04-25 US disclosed
CN-114524829-B Preparation method of imidazo [2,1-b ] thiazole derivative 新疆大学 2024-04-02 CN disclosed
WO-2022165198-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2022-08-04 WO disclosed
CN-114524829-A Preparation method of imidazo [2,1-b ] thiazole derivative 新疆大学 2022-05-24 CN disclosed
WO-2021038419-A1 KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT INSILICO MEDICINE IP LIMITED (CN) 2021-03-04 WO disclosed
CN-111057269-A 2-thiothiazolinyl or 2-thioimidazolinyl terminated mercaptosilane coupling agent and synthesis method and application thereof 怡维怡橡胶研究院有限公司 2020-04-24 CN disclosed
US-4873237-A ANTIULCER AGENTS JOHN WYETH & BROTHER LIMITED (GB) 1989-10-10 US disclosed
US-4772619-A ANTIULCER AGENTS G. D. SEARLE & CO. (US) 1988-09-20 US disclosed
US-4687775-A ANTIULCER AGENTS G. D. SEARLE & CO. (US) 1987-08-18 US disclosed
EP-0204215-A1 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines G.D. Searle & Co. (US) 1986-12-10 EP disclosed
US-4608381-A ANTIARTHRITIC AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1986-08-26 US disclosed
EP-0173664-A2 Biologically active benzimidazole compounds and process for their preparation Aktiebolaget Hässle (SE) 1986-03-05 EP disclosed
EP-0129409-A2 Thiazolo - and thiazinobenzimidazoles JOHN WYETH & BROTHER LIMITED (GB) 1984-12-27 EP disclosed
US-4017507-A ANTIPYRETICS, VIRICIDES, ANTIANAPHYLACTIC SHOCK RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1977-04-12 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132479-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF CUTA, DCXR, PLOD3 FABP6 3186/4885ATM 3602/4885MEN1 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.